Literature DB >> 21343511

Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.

Henriëtte M E Quarles van Ufford1, Thomas C Kwee, Frederik J Beek, Maarten S van Leeuwen, Taro Takahara, Rob Fijnheer, Rutger A J Nievelstein, John M H de Klerk.   

Abstract

OBJECTIVE: The purpose of this study was to compare whole-body MRI including diffusion-weighted imaging (DWI) with (18)F-FDG PET/CT in the staging of newly diagnosed lymphoma. SUBJECTS AND METHODS: Twenty-two consecutively registered patients with newly diagnosed lymphoma prospectively underwent whole-body MRI (22 with T1-weighted, STIR, and DWI sequences and 21 with T1-weighted and STIR sequences but not DWI) and FDG PET/CT. Whole-body MRI-DWI was independently evaluated by two blinded observers. Interobserver agreement was assessed, and whole-body MRI-DWI was compared with FDG PET/CT.
RESULTS: The kappa values for interobserver agreement on whole-body MRI-DWI for all nodal regions together and for all extranodal regions together were 0.676 and 0.452. The kappa values for agreement between whole-body MRI-DWI and FDG PET/CT for all nodal regions together and for all extranodal regions together were 0.597 and 0.507. Ann Arbor stage according to whole-body MRI-DWI findings was concordant with that of FDG PET/CT findings in 77% (17/22) of patients. Understaging and overstaging relative to the findings with FDG PET/CT occurred in 0% (0/22) and 23% (5/22) of cases. In the care of 9% (2/22) of patients, overstaging with whole-body MRI-DWI relative to staging with FDG PET/CT would have had therapeutic consequences.
CONCLUSION: Our early results indicate that overall interobserver agreement on whole-body MRI-DWI findings is moderate to good. Overall agreement between whole-body MRI-DWI and FDG PET/CT is moderate. In the care of patients with newly diagnosed lymphoma, staging with whole-body MRI-DWI does not result in underestimation of stage relative to the results with FDG PET/CT. In a minority of patients, reliance on whole-body MRI-DWI leads to clinically important overstaging relative to the results with FDG PET/CT. FDG PET/CT remains the reference standard for lymphoma staging until larger-scale studies show that use of whole-body MRI-DWI results in correct staging in this minority of cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343511     DOI: 10.2214/AJR.10.4743

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  35 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Whole body MRI of the non-human primate using a clinical 3T scanner: initial experiences.

Authors:  Chun-Xia Li; Xiaodong Zhang
Journal:  Quant Imaging Med Surg       Date:  2017-04

3.  Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.

Authors:  Annalisa Balbo-Mussetto; Chiara Saviolo; Alberto Fornari; Daniela Gottardi; Massimo Petracchini; Annalisa Macera; Chiara Valentina Lario; Teresa Gallo; Corrado Tarella; Stefano Cirillo
Journal:  Radiol Med       Date:  2017-04-18       Impact factor: 3.469

Review 4.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

5.  Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.

Authors:  Asim Afaq; Francesco Fraioli; Harbir Sidhu; Simon Wan; Shonit Punwani; Shih-Hsin Chen; Oguz Akin; David Linch; Kirit Ardeshna; Jonathan Lambert; Kenneth Miles; Ashley Groves; Irfan Kayani
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

6.  Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?

Authors:  Rodrigo Regacini; Andrea Puchnick; Flavio Augusto Vercillo Luisi; Henrique Manoel Lederman
Journal:  Pediatr Radiol       Date:  2018-01-23

7.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

Review 8.  [Extranodal abdominal lymphomas].

Authors:  T F Weber; S Dietrich; J Nattenmüller
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

Review 9.  [Hybrid imaging in lymphoma].

Authors:  Marius E Mayerhöfer; Alexander Haug
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

10.  Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease.

Authors:  Shonit Punwani; King Kenneth Cheung; Nicholas Skipper; Nichola Bell; Alan Bainbridge; Stuart A Taylor; Ashley M Groves; Sharon F Hain; Simona Ben-Haim; Ananth Shankar; Stephen Daw; Steve Halligan; Paul D Humphries
Journal:  Pediatr Radiol       Date:  2013-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.